Shares of Mallinckrodt PLC (NYSE:MNK) have earned a consensus recommendation of “Buy” from the nineteen brokerages that are covering the firm. One research analyst has rated the stock with a sell rating, three have given a hold rating and fifteen have issued a buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $91.52.

A number of research analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Mallinckrodt PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, October 4th. Mizuho dropped their price target on shares of Mallinckrodt PLC from $91.00 to $89.00 and set a “buy” rating on the stock in a research report on Thursday, September 29th. Morgan Stanley reissued a “buy” rating and set a $82.00 price target on shares of Mallinckrodt PLC in a research report on Wednesday, September 21st. Leerink Swann reissued an “outperform” rating and set a $92.00 price target (up from $91.00) on shares of Mallinckrodt PLC in a research report on Friday, September 16th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and set a $105.00 price target (down from $112.00) on shares of Mallinckrodt PLC in a research report on Wednesday, September 7th.

Institutional investors have recently modified their holdings of the stock. Riverhead Capital Management LLC raised its stake in shares of Mallinckrodt PLC by 78.8% in the first quarter. Riverhead Capital Management LLC now owns 139,924 shares of the company’s stock valued at $8,575,000 after buying an additional 61,672 shares during the last quarter. Capital Growth Management LP raised its stake in shares of Mallinckrodt PLC by 69.2% in the first quarter. Capital Growth Management LP now owns 1,125,000 shares of the company’s stock valued at $68,940,000 after buying an additional 460,000 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in shares of Mallinckrodt PLC during the first quarter valued at about $275,000. Rafferty Asset Management LLC raised its stake in shares of Mallinckrodt PLC by 22.8% in the first quarter. Rafferty Asset Management LLC now owns 35,805 shares of the company’s stock valued at $2,194,000 after buying an additional 6,655 shares during the last quarter. Finally, Canada Pension Plan Investment Board raised its stake in shares of Mallinckrodt PLC by 202.8% in the first quarter. Canada Pension Plan Investment Board now owns 19,224 shares of the company’s stock valued at $1,178,000 after buying an additional 12,876 shares during the last quarter. 94.74% of the stock is owned by institutional investors.

Shares of Mallinckrodt PLC (NYSE:MNK) traded down 3.66% on Tuesday, hitting $68.19. 715,710 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $74.03 and its 200 day moving average is $66.71. Mallinckrodt PLC has a 12 month low of $50.90 and a 12 month high of $85.83. The firm has a market cap of $7.34 billion, a P/E ratio of 12.86 and a beta of 1.54.

Mallinckrodt PLC (NYSE:MNK) last released its quarterly earnings results on Tuesday, August 2nd. The company reported $2.20 earnings per share for the quarter, beating analysts’ consensus estimates of $2.00 by $0.20. Mallinckrodt PLC had a net margin of 16.39% and a return on equity of 17.78%. The company had revenue of $970.60 million for the quarter, compared to analyst estimates of $920.35 million. During the same period last year, the firm earned $2.05 earnings per share. The firm’s revenue was up .6% on a year-over-year basis. On average, equities analysts predict that Mallinckrodt PLC will post $7.63 earnings per share for the current year.

Mallinckrodt PLC Company Profile

Mallinckrodt public limited company (Mallinckrodt) is engaged in the specialty pharmaceuticals and nuclear imaging business. The Company develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents. The Company’s segments include Specialty Brands, Specialty Generics and Nuclear Imaging.

5 Day Chart for NYSE:MNK

Receive News & Stock Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related stocks with our FREE daily email newsletter.